Non-Hodgkin's Lymphoma Articles | Page 3

Combinations Continue to Push CLL Field Forward
Jacqueline C. Barrientos, MD, discusses recent combination trials in CLL, and emerging agents in the pipeline.
MCL Expert Highlights Recent Advancements in Field
Peter Martin, MD, reflects on the MCL data presented at the 2017 ASH Annual Meeting, and shares his insight on the future of clinical trials in the disease.
O'Brien Covers Evolution of Ibrutinib in CLL
Susan O’Brien, MD, discusses the impact that has been seen with ibrutinib following the long-term follow-up of the RESONATE studies in chronic lymphocytic leukemia. 
FDA Approval Sought for Duvelisib in CLL, Follicular Lymphoma
A new drug application has been submitted to the FDA for duvelisib for a full approval for relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma and an accelerated approval in relapsed/refractory follicular lymphoma.
Liso-Cel Highly Active in Relapsed/Refractory DLBCL
David G. Maloney, MD, PhD, discusses the promise of lisocabtagene maraleucel in patients with diffuse large B-cell lymphoma.
Novel Antibody Tested in First-Line DLBCL Therapy
Investigators are studying the value of polatuzumab vedotin in patients with intermediate- or high-risk diffuse large B-cell lymphoma.
PF-05280586, a biosimilar for rituximab (Rituxan/MabThera), delivered positive top-line results in the phase III REFLECTIONS B3281006 follicular lymphoma trial.
CHOP-RIT Superior for PFS Versus R-CHOP in High-Risk Follicular Lymphoma
The CHOP-RIT regimen improved progression-free survival compared with R-CHOP alone in previously untreated patients with follicular lymphoma.
Brentuximab Vedotin Approved in Europe for CTCL
Brentuximab vedotin (Adcetris) has been approved by the European Commission for the treatment of patients with CD30-positive cutaneous T-cell lymphoma after at least 1 prior systemic therapy.
Celgene Acquiring Juno Therapeutics for $9 Billion
Celgene has announced plans to acquire Juno Therapeutics, maker of the CAR T-cell therapy lisocabtagene maraleucel (JCAR017), for $87 per share, totaling approximately $9 billion.
Publication Bottom Border
Border Publication